Gene | Score gda | Association Type | Type | Original DB | Sentence supporting the association | PMID | PMID Year | ||||
---|---|---|---|---|---|---|---|---|---|---|---|
|
0.100 | Biomarker | phenotype | HPO | |||||||
|
0.100 | Biomarker | phenotype | HPO | |||||||
|
0.400 | Biomarker | phenotype | HPO | |||||||
|
0.400 | Biomarker | phenotype | CTD_human | Mulibrey nanism: clinical features and diagnostic criteria. | 14757854 | 2004 | ||||
|
0.100 | Biomarker | phenotype | HPO | |||||||
|
0.100 | Biomarker | phenotype | HPO | |||||||
|
0.100 | Biomarker | phenotype | HPO | |||||||
|
0.100 | Biomarker | phenotype | HPO | |||||||
|
0.100 | Biomarker | phenotype | HPO | |||||||
|
0.100 | Biomarker | phenotype | HPO | |||||||
|
0.100 | Biomarker | phenotype | HPO | |||||||
|
0.100 | Biomarker | phenotype | HPO | |||||||
|
0.100 | Biomarker | phenotype | HPO | |||||||
|
0.100 | Biomarker | phenotype | HPO | |||||||
|
0.100 | Biomarker | phenotype | HPO | |||||||
|
0.100 | Biomarker | phenotype | HPO | |||||||
|
0.400 | Biomarker | phenotype | CTD_human | Hepatoprotective effects of diosmin and/or sildenafil against cholestatic liver cirrhosis: The role of Keap-1/Nrf-2 and P38-MAPK/NF-κB/iNOS signaling pathway. | 30026087 | 2018 | ||||
|
0.400 | Biomarker | phenotype | HPO | |||||||
|
0.100 | Biomarker | phenotype | HPO | |||||||
|
0.100 | Biomarker | phenotype | HPO | |||||||
|
0.100 | Biomarker | phenotype | HPO | |||||||
|
0.100 | Biomarker | phenotype | HPO | |||||||
|
0.100 | Biomarker | phenotype | HPO | |||||||
|
0.100 | Biomarker | phenotype | HPO | |||||||
|
0.100 | Biomarker | phenotype | HPO |